Developer docs
API playgroundTry for free, no card

Search company profiles

BiomimX

Full company profile

uuid000cf6b

Namestring
BiomimX
Legal namestring
BiomimX S.r.l.
Websiteurl
biomimx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

BiomimX S.r.l. (founded 2017, Milan, Italy) is a privately held biotech spin-off of Politecnico di Milano that develops beating Organs-on-Chip platforms used as preclinical drug-screening tools. Its patented uBeat® technology delivers controlled mechanical stimulation to 3D microtissues through the uBoX Pro hardware device, replicating native human microenvironments such as heartbeat, peristalsis and mechanical loading without chemical induction. The current product portfolio comprises the uHeart (Heart-on-a-Chip with real-time electrophysiology), uKnee (Cartilage-on-Chip, healthy and osteoarthritic), uGut (gastrointestinal tract with peristalsis and microbiome capability), uScar (cardiac fibrosis), uHep (liver sinusoid), and the multi-organ LivHeart (heart + liver) model, with uLung and uBite in development.

BiomimX monetizes through two streams: (i) hardware product sales of the uBeat® Platform and uBoX Pro to laboratories that wish to run their own organ-on-chip experiments (e.g., Queen Mary University of London as a confirmed equipment customer), and (ii) contract research services using the company's validated human in vitro models for cardiotoxicity screening, drug efficacy studies, and IND-enabling work (used, for example, in Synartro's SYN321 IND submission). Pricing is custom and not publicly disclosed; both products and services are sold via a direct enterprise field-sales motion targeting pharmaceutical, biotech, medical-device, academic and CRO customers across EMEA, North America and Scandinavia.

The company is co-founded and led by CEO Paola Occhetta and President Marco Rasponi (Politecnico di Milano professors), with Roberta Visone as COO. It has been funded almost entirely through non-dilutive sources — Italian government grants (Invitalia Smart&Start, Brevetti+, Regione Lombardia), competition prizes (StartCup Lombardia, Cross the Bridge, TERMIS), H2020 and Horizon Europe consortium participation (SINERGIA, PHOENIX, MIRACLE, IMPLANTEU), and the Berkeley SkyDeck Europe Milan accelerator — with no venture or growth-equity rounds disclosed. In February 2026 BiomimX became a founding member of IAMPS (Industry Alliance for Microphysiological Systems), with its CEO serving as Vice-President for Regulatory Adoption & Partnerships. The company employs 1-10 people and reports no public revenue figure.

Short descriptiontext

BiomimX S.r.l. is an Italian biotech spin-off of Politecnico di Milano that develops patented uBeat® beating Organs-on-Chip (uHeart, uKnee, uGut, uScar, uHep, LivHeart) and sells hardware plus contract research services to pharmaceutical, biotech, medical-device, CRO and academic customers for drug-safety and efficacy screening.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMilan, Italy
HQ citystring
Milan
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organ-on-chip platforms, drug safety screening, in vitro disease models, microphysiological systems, preclinical drug testing
Industry3 codes
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Services-Commercial Physical & Biological Research8731
Product category
Organ-on-Chip Platforms
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales - uBeat® Platform & uBoX Pro
TypeHardware Sales
Description

Sale of hardware platforms and equipment for organ-on-chip research, including the uBeat® Setup supporting culture of 3D microtissue models and the uBoX Pro mechanical stimulation device

biomimx.com
2Contract Research Services
TypeProfessional Services
Description

Fee-for-service testing using company's human in vitro models for drug safety toxicology and efficacy assessment. Services include cardiotoxicity screening, drug efficacy studies, and custom assay development for pharmaceutical and biotech clients

biomimx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1uBeat®
Description

Patented technology platform providing controlled mechanical stimulation to 3D microtissues, mimicking native human tissues. Powers the company's organ-on-chip product line including uHeart, uKnee, uGut, uScar models.

biomimx.com
Core offering1 text field

BiomimX develops and sells the patented uBeat® organ-on-chip platform with the uBoX Pro mechanical stimulation hardware device, enabling the creation of dynamic 3D human microtissue models (heart, cartilage, gut, fibrosis, liver). The company sells this hardware directly to pharmaceutical, biotech, and academic customers, and additionally provides fee-for-service contract research using its validated human in vitro models for drug safety toxicology, cardiotoxicity screening, and efficacy testing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 83.3% sensitivity, 100% specificity, 91.6% accuracy in detecting drug-induced cardiotoxicity
+3 more records
Product overview1 text field

BiomimX is a life sciences company offering the uBeat® Platform as its core technology, which provides mechanical stimulation to generate 3D human microtissue models. The product portfolio centers on this patented platform and includes multiple organ-on-chip models: uHeart (cardiac), uKnee (cartilage/OA), uGut (gastrointestinal), uScar (cardiac fibrosis), uHep (liver), LivHeart (multi-organ heart+liver), uLung, and uBite (both in development). The uBoX Pro is the mechanical stimulation hardware device. The company also provides contract research services using these models for drug discovery, safety-toxicology assessment, and efficacy testing, serving pharmaceutical and biotech companies seeking human-relevant preclinical alternatives to animal testing.

Product and service1 record
1uBeat® Platform & uBoX Pro
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership17 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-10
Description

Founding member of IAMPS, the world's first industry association dedicated to Microphysiological Systems. CEO Paola Occhetta serves as Vice-President for Regulatory Adoption & Partnerships. Association aims to increase regulatory acceptance of MPS data, create data-sharing platforms, and advance device standardization.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic spin-off originating from Politecnico di Milano. Ongoing collaboration through MiMic Lab for technology development and R&D projects including SINERGIA, PHOENIX. Co-founder Marco Rasponi is Professor at Politecnico di Milano.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Non-exclusive commercial agreement following scientific collaboration for drug discovery. Collaboration validated uHeart model with 12 reference compounds for cardiotoxicity detection. Accelera is part of NMS Group.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Research collaboration agreement signed September 2021 for applying Organs-on-Chip solutions to intra-articular medical device discovery process, including uKnee model validation with anti-inflammatory drugs.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration on gut-on-chip model incorporating human fecal samples. uGut publication in Nature Biomedical Engineering February 2025 demonstrating microbiome-immune checkpoint inhibitor interaction predictions.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Scientific partner for knee-on-chip and joint-on-chip development. SNSF/Innosuisse BRIDGE PoC grant collaboration for osteoarthritis model development.

7Politecnico di Torino
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration on cardiac fibrosis model (uScar) and gene therapy testing. Tested innovative gene therapy for cardiac reprogramming in uScar model.

biomimx.com
Strategic tierMinorTypeOthers
Description

Acquired BiomimX uBeat® setup for educational and research facilities. Funded through NC3Rs and BBSRC large infrastructure grant plus commercial partnerships and research grants.

9Humanitas Hospital
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on genetic cardiomyopathy modeling within PHOENIX EU project framework.

biomimx.com
10Synartro
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Swedish biotech company developing anti-OA combined injectable therapy (SYN321). BiomimX provided efficacy data from uKnee model used in IND application for clinical trials.

biomimx.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Strategic commercial partnership for uKnee services signed May 2020.

Strategic tierMinorTypeOthers
Description

Pharmaceutical company client for organ-on-chip testing services.

13UCB
Strategic tierMinorTypeOthers
Description

Pharmaceutical company client for organ-on-chip testing services.

Strategic tierMinorTypeOthers
Description

Consumer health company client for organ-on-chip testing services.

Strategic tierMinorTypeOthers
Description

Healthcare institution client for organ-on-chip services.

16MIRACLE Consortium
Strategic tierMajorTypeStrategic or Co-development Partner
Description

EU-funded Horizon Europe MSCA project (Grant 101119370) focusing on inflammatory regulation in cardiometabolic disease. 13 partner institutions including academic, SMEs, and pharmaceutical companies (AstraZeneca).

biomimx.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

EU-funded Horizon Europe project (Grant 101156638) coordinated by Politecnico di Milano. Develops next-generation OoC platforms for cardiac and neuro-muscular disease modeling. 9 partners over 4 years.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based organ-on-chip pioneer commercializing the Chip-A1 platform across liver, lung, intestine and other tissues. Most direct competitor in MPS-based preclinical testing serving the same pharma/biotech buyer base.

TypeDirect peer
Description

Dutch organ-on-chip company offering the OrganoPlate platform for high-throughput 3D tissue models. Overlapping pharma services model and complementary tissue portfolio, led by a founding executive also in IAMPS leadership.

TypeDirect peer
Description

German multi-organ-chip developer (MOC) with a HUMIMIC platform used for substance testing and ADME applications. Comparable multi-organ positioning and EU regulatory engagement, with overlap in pharma services revenue.

4CN Bio Innovations
TypeDirect peer
Description

UK-based organ-on-chip company with PhysioMimix liver and lung MPS used in drug discovery and toxicology. Direct competitor in MPS-based contract research for pharmaceutical customers.

TypeDirect peer
Description

French organ-on-chip firm offering microfluidic neural and other organ models for industrial applications. Competes in the same MPS vendor landscape and is a fellow IAMPS founding member, with overlapping EU regulatory advocacy.

TypeDirect peer
Description

Swiss 3D in vitro model provider specializing in organoids and microtissues for safety and efficacy testing. Closely comparable in 3D microtissue model offerings (liver, islet, others) and direct CRO-service revenue model.

TypeDirect peer
Description

Italian organ-on-chip company offering the MIVO platform for in vitro testing. Same home-country peer, comparable product/service proposition, and previously co-hosted Italian OoC industry workshops with BiomimX.

TypeDirect peer
Description

Italian start-up developing fluidic and MPS platforms for organ-on-chip research. Direct domestic peer with overlapping EU funding base and co-organized the 2022 Italian Organ-on-Chip industry workshop with BiomimX.

9Kirkstall
TypeDirect peer
Description

UK-based organ-on-chip and microfluidics company offering the Quasi Vivo multi-chamber system for connected tissue culture. Overlaps with BiomimX in pharma toxicology research and the same regulatory acceptance narrative.

TypeBroad incumbent
Description

Large global CRO with a growing portfolio of MPS and organ-on-chip services (e.g., Endosafe, Early Discovery). Represents the incumbent channel threat that could absorb MPS testing demand if BiomimX does not secure regulatory moat.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BiomimX

Organ-on-Chip Platformsbiomimx.com

BiomimX S.r.l. is an Italian biotech spin-off of Politecnico di Milano that develops patented uBeat® beating Organs-on-Chip (uHeart, uKnee, uGut, uScar, uHep, LivHeart) and sells hardware plus contract research services to pharmaceutical, biotech, medical-device, CRO and academic customers for drug-safety and efficacy screening.

What BiomimX does

BiomimX S.r.l. (founded 2017, Milan, Italy) is a privately held biotech spin-off of Politecnico di Milano that develops beating Organs-on-Chip platforms used as preclinical drug-screening tools. Its patented uBeat® technology delivers controlled mechanical stimulation to 3D microtissues through the uBoX Pro hardware device, replicating native human microenvironments such as heartbeat, peristalsis and mechanical loading without chemical induction. The current product portfolio comprises the uHeart (Heart-on-a-Chip with real-time electrophysiology), uKnee (Cartilage-on-Chip, healthy and osteoarthritic), uGut (gastrointestinal tract with peristalsis and microbiome capability), uScar (cardiac fibrosis), uHep (liver sinusoid), and the multi-organ LivHeart (heart + liver) model, with uLung and uBite in development.

BiomimX monetizes through two streams: (i) hardware product sales of the uBeat® Platform and uBoX Pro to laboratories that wish to run their own organ-on-chip experiments (e.g., Queen Mary University of London as a confirmed equipment customer), and (ii) contract research services using the company's validated human in vitro models for cardiotoxicity screening, drug efficacy studies, and IND-enabling work (used, for example, in Synartro's SYN321 IND submission). Pricing is custom and not publicly disclosed; both products and services are sold via a direct enterprise field-sales motion targeting pharmaceutical, biotech, medical-device, academic and CRO customers across EMEA, North America and Scandinavia.

The company is co-founded and led by CEO Paola Occhetta and President Marco Rasponi (Politecnico di Milano professors), with Roberta Visone as COO. It has been funded almost entirely through non-dilutive sources — Italian government grants (Invitalia Smart&Start, Brevetti+, Regione Lombardia), competition prizes (StartCup Lombardia, Cross the Bridge, TERMIS), H2020 and Horizon Europe consortium participation (SINERGIA, PHOENIX, MIRACLE, IMPLANTEU), and the Berkeley SkyDeck Europe Milan accelerator — with no venture or growth-equity rounds disclosed. In February 2026 BiomimX became a founding member of IAMPS (Industry Alliance for Microphysiological Systems), with its CEO serving as Vice-President for Regulatory Adoption & Partnerships. The company employs 1-10 people and reports no public revenue figure.

BiomimX firmographics

Firmographics
Name
BiomimX
Legal name
BiomimX S.r.l.
Website
https://biomimx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
BiomimX S.r.l. is an Italian biotech spin-off of Politecnico di Milano that develops patented uBeat® beating Organs-on-Chip (uHeart, uKnee, uGut, uScar, uHep, LivHeart) and sells hardware plus contract research services to pharmaceutical, biotech, medical-device, CRO and academic customers for drug-safety and efficacy screening.
Ownership category
akta.pro rank

BiomimX industry classification

Industry
Product category
Organ-on-Chip Platforms
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)

Keywords

  • Organ-on-chip platforms
  • Drug safety screening
  • In vitro disease models
  • Microphysiological systems
  • Preclinical drug testing

Where BiomimX is headquartered

Location

Headquarters

HQ city
Milan
HQ country
Italy
HQ region
Europe

Offices2 records

Markets served

BiomimX business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales - uBeat® Platform & uBoX Pro: Sale of hardware platforms and equipment for organ-on-chip research, including the uBeat® Setup supporting culture of 3D microtissue models and the uBoX Pro mechanical stimulation device
  2. Contract Research Services: Fee-for-service testing using company's human in vitro models for drug safety toxicology and efficacy assessment. Services include cardiotoxicity screening, drug efficacy studies, and custom assay development for pharmaceutical and biotech clients

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

BiomimX product offering

Product offering

Core offering

BiomimX develops and sells the patented uBeat® organ-on-chip platform with the uBoX Pro mechanical stimulation hardware device, enabling the creation of dynamic 3D human microtissue models (heart, cartilage, gut, fibrosis, liver). The company sells this hardware directly to pharmaceutical, biotech, and academic customers, and additionally provides fee-for-service contract research using its validated human in vitro models for drug safety toxicology, cardiotoxicity screening, and efficacy testing.

Product overview

BiomimX is a life sciences company offering the uBeat® Platform as its core technology, which provides mechanical stimulation to generate 3D human microtissue models. The product portfolio centers on this patented platform and includes multiple organ-on-chip models: uHeart (cardiac), uKnee (cartilage/OA), uGut (gastrointestinal), uScar (cardiac fibrosis), uHep (liver), LivHeart (multi-organ heart+liver), uLung, and uBite (both in development). The uBoX Pro is the mechanical stimulation hardware device. The company also provides contract research services using these models for drug discovery, safety-toxicology assessment, and efficacy testing, serving pharmaceutical and biotech companies seeking human-relevant preclinical alternatives to animal testing.

Differentiator

Problem solved

Functional benefit

Brands

  • uBeat®: Patented technology platform providing controlled mechanical stimulation to 3D microtissues, mimicking native human tissues. Powers the company's organ-on-chip product line including uHeart, uKnee, uGut, uScar models.

Products and services

  • uBeat® Platform & uBoX Pro

Quantifiable outcome

  • 83.3% sensitivity, 100% specificity, 91.6% accuracy in detecting drug-induced cardiotoxicity
  • +3 more outcomes

Companies that use BiomimX

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

BiomimX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

BiomimX partnerships and signals

Strategic signal

Partnerships

17 partnerships are on record, tiered core, major and minor.

  • IAMPS (Industry Alliance for Microphysiological Systems)coreStrategic or Co-development Partner · 10 February 2026Founding member of IAMPS, the world's first industry association dedicated to Microphysiological Systems. CEO Paola Occhetta serves as Vice-President for Regulatory Adoption & Partnerships. Association aims to increase regulatory acceptance of MPS data, create data-sharing platforms, and advance device standardization.
  • Politecnico di MilanocoreStrategic or Co-development PartnerAcademic spin-off originating from Politecnico di Milano. Ongoing collaboration through MiMic Lab for technology development and R&D projects including SINERGIA, PHOENIX. Co-founder Marco Rasponi is Professor at Politecnico di Milano.
  • Accelera SrlcoreStrategic or Co-development PartnerNon-exclusive commercial agreement following scientific collaboration for drug discovery. Collaboration validated uHeart model with 12 reference compounds for cardiotoxicity detection. Accelera is part of NMS Group.
  • Fidia FarmaceuticimajorStrategic or Co-development PartnerResearch collaboration agreement signed September 2021 for applying Organs-on-Chip solutions to intra-articular medical device discovery process, including uKnee model validation with anti-inflammatory drugs.
  • Istituto Europeo di Oncologia (IEO)majorStrategic or Co-development PartnerCollaboration on gut-on-chip model incorporating human fecal samples. uGut publication in Nature Biomedical Engineering February 2025 demonstrating microbiome-immune checkpoint inhibitor interaction predictions.
  • University of BaselmajorStrategic or Co-development PartnerScientific partner for knee-on-chip and joint-on-chip development. SNSF/Innosuisse BRIDGE PoC grant collaboration for osteoarthritis model development.
  • Politecnico di TorinomajorStrategic or Co-development PartnerCollaboration on cardiac fibrosis model (uScar) and gene therapy testing. Tested innovative gene therapy for cardiac reprogramming in uScar model.
  • Queen Mary University of LondonminorOthersAcquired BiomimX uBeat® setup for educational and research facilities. Funded through NC3Rs and BBSRC large infrastructure grant plus commercial partnerships and research grants.
  • Humanitas HospitalminorStrategic or Co-development PartnerCollaboration on genetic cardiomyopathy modeling within PHOENIX EU project framework.
  • SynartromajorChannel Partner/ Reseller/ DistributorSwedish biotech company developing anti-OA combined injectable therapy (SYN321). BiomimX provided efficacy data from uKnee model used in IND application for clinical trials.
  • NeuroZone SrlminorChannel Partner/ Reseller/ DistributorStrategic commercial partnership for uKnee services signed May 2020.
  • ChiesiminorOthersPharmaceutical company client for organ-on-chip testing services.
  • UCBminorOthersPharmaceutical company client for organ-on-chip testing services.
  • HaleonminorOthersConsumer health company client for organ-on-chip testing services.
  • Charité BerlinminorOthersHealthcare institution client for organ-on-chip services.
  • MIRACLE ConsortiummajorStrategic or Co-development PartnerEU-funded Horizon Europe MSCA project (Grant 101119370) focusing on inflammatory regulation in cardiometabolic disease. 13 partner institutions including academic, SMEs, and pharmaceutical companies (AstraZeneca).
  • PHOENIX ConsortiummajorStrategic or Co-development PartnerEU-funded Horizon Europe project (Grant 101156638) coordinated by Politecnico di Milano. Develops next-generation OoC platforms for cardiac and neuro-muscular disease modeling. 9 partners over 4 years.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

BiomimX competitors and assessment

Company assessment

Direct peers

  • Emulate: US-based organ-on-chip pioneer commercializing the Chip-A1 platform across liver, lung, intestine and other tissues. Most direct competitor in MPS-based preclinical testing serving the same pharma/biotech buyer base.
  • MIMETAS: Dutch organ-on-chip company offering the OrganoPlate platform for high-throughput 3D tissue models. Overlapping pharma services model and complementary tissue portfolio, led by a founding executive also in IAMPS leadership.
  • TissUse: German multi-organ-chip developer (MOC) with a HUMIMIC platform used for substance testing and ADME applications. Comparable multi-organ positioning and EU regulatory engagement, with overlap in pharma services revenue.
  • CN Bio Innovations: UK-based organ-on-chip company with PhysioMimix liver and lung MPS used in drug discovery and toxicology. Direct competitor in MPS-based contract research for pharmaceutical customers.
  • NETRI: French organ-on-chip firm offering microfluidic neural and other organ models for industrial applications. Competes in the same MPS vendor landscape and is a fellow IAMPS founding member, with overlapping EU regulatory advocacy.
  • InSphero: Swiss 3D in vitro model provider specializing in organoids and microtissues for safety and efficacy testing. Closely comparable in 3D microtissue model offerings (liver, islet, others) and direct CRO-service revenue model.
  • React4Life: Italian organ-on-chip company offering the MIVO platform for in vitro testing. Same home-country peer, comparable product/service proposition, and previously co-hosted Italian OoC industry workshops with BiomimX.
  • IVTech Srl: Italian start-up developing fluidic and MPS platforms for organ-on-chip research. Direct domestic peer with overlapping EU funding base and co-organized the 2022 Italian Organ-on-Chip industry workshop with BiomimX.
  • Kirkstall: UK-based organ-on-chip and microfluidics company offering the Quasi Vivo multi-chamber system for connected tissue culture. Overlaps with BiomimX in pharma toxicology research and the same regulatory acceptance narrative.

Broad incumbents

  • Charles River Laboratories: Large global CRO with a growing portfolio of MPS and organ-on-chip services (e.g., Endosafe, Early Discovery). Represents the incumbent channel threat that could absorb MPS testing demand if BiomimX does not secure regulatory moat.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

BiomimX social profiles

Digital presence

BiomimX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BiomimX leadership team

Management profile

Number of profiles

Profiles3 records

BiomimX funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BiomimX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BiomimX

What does BiomimX do?

BiomimX develops and sells the patented uBeat® organ-on-chip platform with the uBoX Pro mechanical stimulation hardware device, enabling the creation of dynamic 3D human microtissue models (heart, cartilage, gut, fibrosis, liver). The company sells this hardware directly to pharmaceutical, biotech, and academic customers, and additionally provides fee-for-service contract research using its validated human in vitro models for drug safety toxicology, cardiotoxicity screening, and efficacy testing.

Is BiomimX a public or private company?

BiomimX is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BiomimX founded?

BiomimX was founded in 2017. It employs 11 to 50 people.

Where is BiomimX based?

BiomimX is headquartered in Milan, Italy, in the Europe region.

How does BiomimX make money?

Two revenue lines are on record. Product Sales - uBeat® Platform & uBoX Pro is the primary driver. The others are contract Research Services.

Who are BiomimX's main competitors?

Direct peers on record are Emulate, MIMETAS, TissUse, CN Bio Innovations, NETRI, InSphero, React4Life, IVTech Srl and Kirkstall. Charles River Laboratories is listed as a broad incumbent.

Does BiomimX have an API?

No public API is recorded for BiomimX.

What industry is BiomimX in?

BiomimX's product category is Organ-on-Chip Platforms. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541714 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireIndustry Leaders Announce World’s First Microphysiological Systems Industry Association (IAMPS)European MPS industry leaders announced the creation of the Industry Alliance for Microphysiological Systems (IAMPS), the world's first industry association dedicated to representing microphysiological systems providers across Europe. The founding members include nine companies: Alveolix, BiomimX, Chiron, Dynamic42, InSphero, MIMETAS, NETRI, React4Life, and TissUse, headquartered in Switzerland, Italy, the Netherlands, Germany, and France. IAMPS will work to increase regulatory acceptance of MPS data, create data-sharing platforms, and advance device standardization, with the association expected to become operational in Q2 2026.openPR.comGlobal Organ-on-Chip Market: Breakthrough Technologies & Industry To Reach USD 796.7 Million by 2031| Emulate Inc., Mimetas B.V., Insphero, Organovo Holdings, CN Bio Innovations Ltd, BiomimX S.r.lThe global organ-on-chip market reached USD 107.5 million in 2022 and is projected to reach USD 796.7 million by 2031, a CAGR of 29.6%. Key players include Emulate, Mimetas, and Organovo, with recent investments in AxoSim and CN Bio Innovations.BiomimxBiomimXThe article presents a chronological history of awards, grants, and recognitions received by BiomimX between 2016 and November 2023. Key milestones include winning the GrandPrixInnovation third prize in 2023, selection for the Berkeley SkyDeck Europe accelerator in 2022, and various funding from entities like Invitalia, Regione Lombardia, and the European Commission's Horizon 2020 program. The text highlights the company's development through competitions such as Cross the Bridge and StartCup Lombardia, alongside academic collaborations with Politecnico di Milano and University Hospital of Basel.PR NewswireGlobal Organ-on-a-Chip Markets Research Report 2022 with Profiles of Leading Players - 4Dcell, BiomimX, Emulate, Kirkstall, Nortis and TissUseResearch and Markets has added a new market research report titled "Organ-on-a-Chip: Global Markets" to its offerings, covering market trends, segmentation, and forecasts through 2026. The report profiles leading industry players such as Emulate Inc., BiomimX, and 4Dcell while analyzing drivers like the shift away from animal testing and rising demand for personalized medicine. It also details regional dynamics, with North America holding the largest market share due to extensive R&D activities.